WHO Issues Warning Over Severe Lack of Weight-Loss Medications
Under 10% of people that would benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it publishes its first advice on the therapies.
Given more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a long-term condition that can be addressed with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key barriers to widespread access to the jabs that can help people shift substantial weight, explains the organization.
Weight-Loss Drug Scarcity
Even under the current most favorable outlook, the production of these medications could only cover around 100 million people – less than 10% of the global need, per the health organization.
The guideline encourages nations and manufacturers to increase availability, by approaches including licensing agreements.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is due to expire in several countries in 2026.
The Way Weight-Loss Drugs Function
The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and enhance satiety so people eat less.
Individuals usually see weight reduction within a few weeks of beginning the weekly injections.
Evidence indicates people may see weight return a year later of halting the medication, as their usual food cravings resume.
To be carrying excess weight raises your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Obesity impacts individuals in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, as per the health agency.
